Skip to main content
Sinocare Inc. logo

Sinocare Inc. — Investor Relations & Filings

Ticker · 300298 ISIN · CNE100001CJ0 LEI · 3003008DEKI00A51LU77 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,250 across all filing types
Latest filing 2026-05-22 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300298

About Sinocare Inc.

https://www.sinocare.com

Sinocare Inc. specializes in the research, development, and manufacturing of biosensor technology and rapid testing products for chronic disease management. The company is primarily recognized for its blood glucose monitoring systems, including meters and test strips, which serve a global patient base. Its product portfolio extends to point-of-care testing (POCT) solutions for HbA1c, uric acid, blood lipids, and other metabolic indicators. Through the integration of advanced sensing technologies and digital health platforms, Sinocare provides comprehensive diagnostic tools for diabetes and related metabolic disorders. The company focuses on delivering affordable and accurate monitoring solutions to improve the quality of life for individuals with chronic conditions worldwide.

Recent filings

Filing Released Lang Actions
关于回购公司股份比例达到1%的进展公告
Transaction in Own Shares Classification · 92% confidence The document is a progress announcement for the company’s share repurchase program, detailing the number of shares repurchased, percentage of total share capital, prices, regulatory compliance, and next steps. This clearly fits the definition of a Transaction in Own Shares (share buyback) announcement.
2026-05-22 Chinese
关于召开2025年年度股东会的提示性公告
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a detailed notice to convene the company’s 2025 Annual General Meeting, including agenda items for shareholder voting, proxy forms, registration procedures, meeting logistics, and attachments (proxy authorization, registration form, etc.). This corresponds to materials sent to shareholders to provide information and solicit proxies for a shareholders’ meeting, which fits the “Proxy Solicitation & Information Statement” category.
2026-05-21 Chinese
北京植德律师事务所关于三诺生物传感股份有限公司第二期员工持股计划调整事项的法律意见书
Regulatory Filings Classification · 75% confidence The document is a legal opinion letter (法律意见书) provided by a law firm regarding adjustments to an employee share ownership plan. It does not present financial statements, earnings data, or a shareholder vote result, nor is it an agenda or presentation; instead, it is a certification/legal compliance document required for regulatory submission. There is no category explicitly for legal opinion letters, so under the fallback provisions for officer attestations and regulatory compliance documents, this should be classified as a Regulatory Filing.
2026-05-15 Chinese
关于控股股东部分股份质押展期的公告
Regulatory Filings Classification · 82% confidence The document is an official announcement by Sinocare’s board disclosing an extension of share pledges by its controlling shareholder. It does not present financial statements or results (excluding 10-K/IR/ER), no board changes (MANG), no dividend (DIV), no voting results (DVA), no capital issuance (SHA), nor insider trading of buying/selling shares (DIRS). It is a routine compliance disclosure about shareholder collateral arrangements, which does not fit into any narrowly defined category, so it falls under the general regulatory announcement/fallback category.
2026-05-11 Chinese
关于首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Sinocare about the company's first share repurchase (buyback) activity. It details the number of shares repurchased, prices, total amount spent, and compliance with regulatory guidelines. The text references the company's board meeting and shareholder meeting approvals for the buyback plan and states that the repurchase was conducted according to the approved plan and relevant laws. The document is relatively short (1308 characters) and focuses on the share repurchase event itself, not a broader financial report or earnings release. This matches the definition of a Transaction in Own Shares (POS) filing, which covers company announcements about buying back or selling its own shares.
2026-05-08 Chinese
关于召开2026年第一次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2026 first extraordinary general meeting (临时股东会) of 三诺生物传感股份有限公司. It includes information about the meeting date, voting procedures (both onsite and online), agenda items for shareholder approval (such as share repurchase plans and amendments to the articles of association), registration details, and attachments like proxy forms and legal representative certificates. The document is a formal announcement to shareholders about the meeting and the proposals to be voted on, rather than the results of the meeting or the minutes. It does not contain financial statements or management discussion and analysis. The document length is about 6415 characters, which is consistent with a detailed meeting notice. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), which is used to provide shareholders with information and request votes for meetings.
2026-03-27 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.